|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US5914129A
(en)
*
|
1996-07-23 |
1999-06-22 |
Mauskop; Alexander |
Analgesic composition for treatment of migraine headaches
|
|
US6103260A
(en)
|
1997-07-17 |
2000-08-15 |
Mcneil-Ppc, Inc. |
Simethicone/anhydrous calcium phosphate compositions
|
|
DE10228326A1
(de)
*
|
2002-06-25 |
2004-01-22 |
Heribert Dr.med. Bohlen |
Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
|
|
US20040076668A1
(en)
|
2002-07-03 |
2004-04-22 |
Pfizer Inc. |
Controlled-release pharmaceutical formulations
|
|
AU2004222378B2
(en)
|
2003-03-14 |
2008-08-14 |
Merck Sharp & Dohme Corp. |
Carboxamide spirohydantoin CGRP receptor antagonists
|
|
CA2519515A1
(en)
|
2003-03-14 |
2004-10-14 |
Merck & Co., Inc. |
Benodiazepine spirohydantoin cgrp receptor antagonists
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
WO2005041869A2
(en)
|
2003-10-24 |
2005-05-12 |
Josef Rettenmaier & Soehne Gmbh & Co., Kg |
Process for co-spray drying agents with dry silicified mcc
|
|
CA2579847A1
(en)
|
2004-09-13 |
2006-03-23 |
Merck & Co., Inc. |
Bicyclic anilide spirolactam cgrp receptor antagonists
|
|
US7390798B2
(en)
|
2004-09-13 |
2008-06-24 |
Merck & Co., Inc. |
Carboxamide spirolactam CGRP receptor antagonists
|
|
DE102004063755A1
(de)
|
2004-12-29 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
|
|
CA2599925A1
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
|
WO2007092642A2
(en)
|
2006-02-09 |
2007-08-16 |
Merck & Co., Inc. |
Polymer formulations of cetp inhibitors
|
|
AU2007284994B2
(en)
|
2006-05-09 |
2010-04-22 |
Merck Sharp & Dohme Corp. |
Substituted spirocyclic CGRP receptor antagonists
|
|
CA2689217C
(en)
|
2007-06-05 |
2016-02-16 |
Merck & Co., Inc. |
Carboxamide heterocyclic cgrp receptor antagonists
|
|
KR20100091972A
(ko)
|
2007-10-18 |
2010-08-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ｃｇｒｐ 길항제
|
|
WO2009065922A2
(de)
|
2007-11-22 |
2009-05-28 |
Boehringer Ingelheim International Gmbh |
Organische verbindungen
|
|
CA2722536A1
(en)
|
2008-02-05 |
2009-08-13 |
Merck & Co., Inc. |
Prodrugs of cgrp receptor antagonist
|
|
US8044043B2
(en)
|
2008-04-11 |
2011-10-25 |
Bristol-Myers Squibb Company |
CGRP receptor antagonists
|
|
US20150023888A1
(en)
|
2008-09-05 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
|
|
WO2010114801A1
(en)
|
2009-03-31 |
2010-10-07 |
Ligand Pharmaceuticals Inc. |
Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
|
|
WO2010139717A1
(de)
|
2009-06-05 |
2010-12-09 |
Boehringer Ingelheim International Gmbh |
Neue verbindungen
|
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
WO2012064911A1
(en)
|
2010-11-12 |
2012-05-18 |
Merck Sharp & Dohme Corp. |
Piperidinone carboxamide indane cgrp receptor antagonists
|
|
TWI501968B
(zh)
|
2010-11-12 |
2015-10-01 |
Merck Sharp & Dohme |
六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
|
|
WO2013066360A1
(en)
|
2010-12-22 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
|
|
US8895572B2
(en)
|
2010-12-22 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic indane carboxamide CGRP receptor antagonists
|
|
US8591944B2
(en)
|
2011-03-08 |
2013-11-26 |
Zalicus Pharmaceuticals Ltd. |
Solid dispersion formulations and methods of use thereof
|
|
EP2685826B1
(en)
|
2011-03-18 |
2016-02-03 |
Merck Sharp & Dohme Corp. |
Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
|
|
WO2013036861A1
(en)
|
2011-09-08 |
2013-03-14 |
Codexis, Inc |
Biocatalysts and methods for the synthesis of substituted lactams
|
|
KR102061180B1
(ko)
|
2012-03-14 |
2019-12-31 |
머크 샤프 앤드 돔 코포레이션 |
비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염
|
|
US9487523B2
(en)
|
2012-03-14 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Process for making CGRP receptor antagonists
|
|
US9833488B2
(en)
|
2012-04-25 |
2017-12-05 |
Centric Research Institute |
Sensitization composition and method of use
|
|
EP2846798B1
(en)
|
2012-05-09 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam cgrp receptor antagonists
|
|
US9174989B2
(en)
|
2012-05-09 |
2015-11-03 |
Merck Sharp & Dohme Corp. |
Process for making CGRP receptor antagonists
|
|
EP2846801B1
(en)
|
2012-05-09 |
2017-04-05 |
Merck Sharp & Dohme Corp. |
Pyridine cgrp receptor antagonists
|
|
EP2846799B1
(en)
|
2012-05-09 |
2017-11-15 |
Merck Sharp & Dohme Corp. |
Spirolactam cgrp receptor antagonists
|
|
SMT202400324T1
(it)
|
2013-03-15 |
2024-11-15 |
Tonix Pharma Ltd |
Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
|
|
BR112016005589B8
(pt)
|
2013-09-16 |
2023-04-18 |
Merck Sharp & Dohme |
Composição farmacêutica líquida, e, uso da mesma
|
|
US20240180883A1
(en)
|
2020-12-22 |
2024-06-06 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
US12168004B2
(en)
|
2014-02-05 |
2024-12-17 |
Merck Sharp & Dohme Llc |
Treatment of migraine
|
|
RU2019123406A
(ru)
|
2014-02-05 |
2019-10-03 |
Мерк Шарп И Доум Корп. |
Технология приготовления таблеток для cgrp-активных соединений
|
|
WO2015120014A1
(en)
|
2014-02-05 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Novel disintegration systems for pharmaceutical dosage forms
|
|
JP2017512757A
(ja)
|
2014-02-24 |
2017-05-25 |
ウリゲン ファーマシューティカルズ、インコーポレイテッド |
経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
|
|
AU2015305696B2
(en)
|
2014-08-22 |
2019-08-29 |
Pharma& Schweiz Gmbh |
High dosage strength tablets of rucaparib
|
|
JP6673924B2
(ja)
|
2015-01-23 |
2020-03-25 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
|
|
MX2018003713A
(es)
|
2015-09-24 |
2018-08-15 |
Teva Pharmaceuticals Int Gmbh |
Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
|
|
US20180092899A1
(en)
|
2016-09-30 |
2018-04-05 |
Merck Sharp & Dohme Corp. |
Method of treating acute migraine with cgrp-active compound
|
|
RU2770066C2
(ru)
|
2017-03-02 |
2022-04-14 |
Бет Изрейэл Диконисс Медикал Сентер, Инк. |
Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
|
|
TWI754772B
(zh)
|
2017-09-06 |
2022-02-11 |
美商美國禮來大藥廠 |
用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
|
|
US20190135927A1
(en)
|
2017-09-29 |
2019-05-09 |
Bhl Patent Holdings, Llc |
Migraine, headache, chronic pain treatment, and prophylaxis options
|
|
US20200353088A1
(en)
|
2017-11-06 |
2020-11-12 |
Auckland Uniservices Limited |
Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
|
|
US20190374518A1
(en)
|
2018-06-08 |
2019-12-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
US20190374520A1
(en)
|
2018-06-08 |
2019-12-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
TWI826514B
(zh)
|
2018-09-04 |
2023-12-21 |
美商美國禮來大藥廠 |
用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
|
|
MX2021008191A
(es)
|
2019-01-20 |
2021-08-11 |
Biohaven Pharm Holding Co Ltd |
Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
|
|
AU2020259461A1
(en)
|
2019-04-18 |
2021-11-11 |
Allergan Sales, Llc |
CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
|
|
US20210121541A1
(en)
|
2019-07-05 |
2021-04-29 |
Allergan Pharmaceuticals International Limited |
CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
|
|
WO2021062282A1
(en)
|
2019-09-25 |
2021-04-01 |
Allergan Pharmaceuticals International Limited |
Combination therapy with cgrp antagonists
|
|
AR120360A1
(es)
*
|
2019-10-31 |
2022-02-09 |
Scherer Technologies Llc R P |
Cápsula de supositorio
|
|
CN116390712A
(zh)
|
2020-07-29 |
2023-07-04 |
阿勒根制药国际有限公司 |
治疗偏头痛
|
|
CA3206184A1
(en)
|
2020-12-22 |
2022-06-30 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
EP4408418A1
(en)
|
2021-09-27 |
2024-08-07 |
Allergan Pharmaceuticals International Limited |
Combination comprising atogepant for treating migraine
|
|
MX2024010878A
(es)
|
2022-03-09 |
2024-09-17 |
Allergan Pharmaceuticals Int Ltd |
Tratamiento preventivo de la migra?a.
|
|
WO2024081718A1
(en)
|
2022-10-11 |
2024-04-18 |
Allergan Pharmaceuticals International Limited |
Cgrp receptor antagonist for the treatment of migraine
|